PCM
SUPN icon

Piermont Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Piermont Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-7,100
Closed -$425K – 202
2018
Q2 		$425K Sell
7,100
-1,270
-15% -$65.8K 0.13% 171
2018
Q1 		$383K Sell
8,370
-1,390
-14% -$58K 0.13% 198
2017
Q4 		$389K Sell
9,760
-530
-5% -$20.9K 0.13% 200
2017
Q3 		$412K Sell
10,290
-10,924
-51% -$473K 0.14% 190
2017
Q2 		$914K Sell
21,214
-9,927
-32% -$353K 0.26% 153
2017
Q1 		$975K Hold
31,141
– – 0.23% 158
2016
Q4 		$786K Sell
31,141
-600
-2% -$13.4K 0.18% 181
2016
Q3 		$785K Sell
31,741
-36,140
-53% -$818K 0.19% 186
2016
Q2 		$1.38M Buy
67,881
+32,756
+93% +$581K 0.36% 103
2016
Q1 		$536K Buy
35,125
+1,335
+4% +$17.4K 0.17% 136
2015
Q4 		$454K Sell
33,790
-2,270
-6% -$35.1K 0.14% 155
2015
Q3 		$506K Sell
36,060
-24,930
-41% -$464K 0.17% 129
2015
Q2 		$1.04M Hold
60,990
– – 0.31% 102
2015
Q1 		$737K Buy
60,990
+20,610
+51% +$195K 0.22% 111
2014
Q4 		$335K Buy
+40,380
New +$339K 0.12% 162

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Piermont Capital Management's SUPN Position: Q3 2018 in Review

Piermont Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 7,100 shares — an estimated $425K sold.

Piermont Capital Management first reported a position in SUPN in Q4 2014 and held it in 15 quarters. The position peaked at $1.38M in Q2 2016. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

  • Piermont Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piermont Capital Management sold 7,100 Supernus Pharmaceuticals shares in Q3 2018, an estimated $425K.
  • Piermont Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 15 quarters.
  • Piermont Capital Management's Supernus Pharmaceuticals position peaked at $1.38M in Q2 2016.
  • 288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.